Conflict of interest: M. Wijsenbeek reports grants from The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Organization, Sarcoidosis.nl, Boehringer Ingelheim, Hoffman la Roche and AstraZeneca-Daiichi, consulting fees from Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, Hoffman la Roche, Horizon Therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, Thyron, Trevi and Vicore, lecture honoraria from Boehringer Ingelheim, CSL Behring, Hoffman la Roche and Novartis, travel support from Boehringer Ingelheim, Hoffman la Roche and Galapagos, advisory board participation with Savara and Galapagos, leadership roles as Chair of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, member of the board of the Netherlands Respiratory Society, member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and related disorders federation, and chair of the educational committee of the European Reference Network for rare Lung Diseases, and is a member of the advisory board of the Dutch Lung Fibrosis and Sarcoidosis patient associations, outside the submitted work. C. Valenzuela reports consulting fees from Boehringer Ingelheim, Hoffmann-La Roche Ltd and BMS, and lecture honoraria and travel support from Boehringer Ingelheim, outside the submitted work. A. Holland reports grants from Medical Research Future Fund, Australia, National Health and Medical Research Council, Australia, and iCare NSW, Australia, and a leadership role as President, Thoracic Society of Australia and New Zealand, outside the submitted work.